Actinium-225 dendrimer-radioconjugates combined with low-dose standard-of-care chemotherapy: site-independent treatment of triple negative breast cancer metastases
Pooja Hariharan, Rajiv Nair, Aira Sarkar, Kathleen L. Gabrielson, Tony Wu, Chang Liu, Wathsala Liyanage, Rangaramanujam M. Kannan, Stavroula Sofou
This study evaluates dendrimer-radioconjugates with Actinium-225 and low-dose cisplatin for treating metastatic triple negative breast cancer across different anatomical sites in mice, showing improved survival without long-term toxicity.
bioRxiv · Aug 25, 2025 · PreprintBioengineering